Skip to main content
PeerJ logoLink to PeerJ
. 2019 Nov 13;7:e8049. doi: 10.7717/peerj.8049

Prediction of clusters of miRNA binding sites in mRNA candidate genes of breast cancer subtypes

Dana Aisina 1,#, Raigul Niyazova 1, Shara Atambayeva 1, Anatoliy Ivashchenko 1,✉,#
Editor: Tatiana Tatarinova
PMCID: PMC6858813  PMID: 31741798

Abstract

The development of breast cancer (BC) subtypes is controlled by distinct sets of candidate genes, and the expression of these genes is regulated by the binding of their mRNAs with miRNAs. Predicting miRNA associations and target genes is thus essential when studying breast cancer. The MirTarget program identifies the initiation of miRNA binding to mRNA, the localization of miRNA binding sites in mRNA regions, and the free energy from the binding of all miRNA nucleotides with mRNA. Candidate gene mRNAs have clusters (miRNA binding sites with overlapping nucleotide sequences). mRNAs of EPOR, MAZ and NISCH candidate genes of the HER2 subtype have clusters, and there are four clusters in mRNAs of MAZ, BRCA2 and CDK6 genes. Candidate genes of the triple-negative subtype are targets for multiple miRNAs. There are 11 sites in CBL mRNA, five sites in MMP2 mRNA, and RAB5A mRNA contains two clusters in each of the three sites. In SFN mRNA, there are two clusters in three sites, and one cluster in 21 sites. Candidate genes of luminal A and B subtypes are targets for miRNAs: there are 21 sites in FOXA1 mRNA and 15 sites in HMGA2 mRNA. There are clusters of five sites in mRNAs of ITGB1 and SOX4 genes. Clusters of eight sites and 10 sites are identified in mRNAs of SMAD3 and TGFB1 genes, respectively. Organizing miRNA binding sites into clusters reduces the proportion of nucleotide binding sites in mRNAs. This overlapping of miRNA binding sites creates a competition among miRNAs for a binding site. From 6,272 miRNAs studied, only 29 miRNAs from miRBase and 88 novel miRNAs had binding sites in clusters of target gene mRNA in breast cancer. We propose using associations of miRNAs and their target genes as markers in breast cancer subtype diagnosis.

Keywords: Binding site, Cluster, Gene, Breast cancer, miRNA

Introduction

Breast cancer (BC) is the most common cancer in women worldwide, and the second most common cancer overall. Statistics indicate an intense, steady increase in the incidence and mortality of BC among women (Benson & Jatoi, 2012). More than 50% of BC cases are first detected in the late stages of the disease. Every year, 1,400,000 new cases of the disease are diagnosed globally (Jemal et al., 2010). Establishing the relationship between the miRNAs and mRNA genes involved in the development of BC (candidate genes) is a promising area of research. miRNAs are found in tumors and blood, and may be potential biomarkers of BC (Adhami et al., 2018; Hannafon et al., 2016; Kurozumi et al., 2017; Lagendijk et al., 2018; McDermott et al., 2014; Piasecka et al., 2018; Zhang et al., 2017). Several studies have been devoted to establishing a correlation between the expression of miRNA and various BC subtypes (Biagioni et al., 2012; Blenkiron et al., 2007; Enerly et al., 2011; Lee et al., 2013; Lowery et al., 2009; Mattie et al., 2006; Telonis et al., 2015; Yang et al., 2017). Disruptions in the regulation of miRNA expression can regulate the expression of oncogenes and oncosuppressors, thus affecting the development of a tumor. An increase or decrease in the expression of certain miRNAs influence the onset and progression of a tumor (Wang et al., 2013). Some miRNAs are overexpressed if the expression of candidate genes in both benign and malignant tumors is significantly lowered (Tahiri et al., 2014). It has been shown that many intron miRNAs are expressed together with host genes. Changes in miRNA expression may be associated with chromosomal mutations (Qian et al., 2012), epigenetic modifications (Yu et al., 2013) or biogenesis defects (Sung et al., 2012). miRNAs that inhibit the translation of tumor suppressor and apoptosis gene mRNA function as oncogenes, which contributes to oncogenesis (Wu et al., 2013). Other miRNAs may be tumor suppressors if their target genes are oncogenes and cell cycle genes (Nian et al., 2013). Presently, there is little information about miRNA and genes involved in BC subtypes. Therefore, in the present work, the association between the miRNAs and mRNAs of candidate genes of BC subtypes are revealed. According to miRBase, more than 90% of miRNA have a length in the range of 20–25 nucleotides (http://mirbase.org). Similar to the length of primers in the polymerase chain reaction, miRNA nucleotide sequence length is necessary for the selective interaction with mRNA (Huggett & O’Grady, 2014). One miRNA can have binding sites (BSs) in the mRNA of many genes (Atambayeva et al., 2017; Ivashchenko et al., 2016; Niyazova et al., 2015), and the mRNA of one gene can have BSs for many miRNAs (Kondybayeva et al., 2018).

In this article, we show the advantage of utilizing the interaction between miRNA and mRNA when studying the binding of miRNA with the mRNA of BC subtype candidate genes, which contain clusters of miRNA BSs.

Materials & Methods

The nucleotide (nt) sequences of candidate genes of BC subtypes were downloaded from GenBank (http://www.ncbi.nlm.nih.gov). These specific candidate genes are responsible for the development of triple-negative subtype, luminal A and B subtypes, and HER2 subtype of BC (Table S1). Information about miRNAs that presumably bind to candidate genes of BC is provided in Table S2. The table indicates that the miRNAs studied are present in blood, serum, plasma, and cells in BC or other types of cancer. The nucleotide sequences of mRNA genes of Chlorocebus sabaeus—Csa, Gorilla gorilla—Ggo, Homo sapience—Hsa, Macaca mulatta—Mml, Mus musculus—Mmu, Pan paniscus—Ppa, Pan troglodytes—Ptr, Papio Anubis—Pan, Pongo abelii—Pab, and Rattus norvegicus—Rno were downloaded from NCBI (http://www.ncbi.nlm.nih.gov). The nucleotide sequences of 2,565 miRNAs were taken from miRBase, and 3,707 miRNAs from a previous study (Londin et al., 2015). The Reads Per Kilobase Million (RPKM) value (Mortazavi et al., 2008) was given in the Human Protein Atlas data (https://www.proteinatlas.org/ENSG00000150093-ITGB1/tissue/breast). Human Protein Atlas data were used as a quantitative measure of breast transcript expression.

The miRNA BSs in 5′UTRs, CDSs and 3′UTRs of several genes were predicted using the MirTarget program (Ivashchenko et al., 2016; Ivashchenko, Issabekova & Berillo, 2013). This program defines the following features of miRNA binding to mRNAs: (a) the start of the initiation of miRNA binding to mRNAs; (b) the localization of miRNA BSs in 5′UTRs, CDSs and 3′UTRs of the mRNAs; (c) the free energy of interaction between miRNA and the mRNA (ΔG, kJ/mole); and (d) the schemes of nucleotide interactions between miRNAs and mRNAs. The ratio ΔG/ΔGm (%) was determined for each site (ΔGm equals the free energy of miRNA binding with its fully complementary nucleotide sequence). The miRNA BSs located in mRNAs had ΔG/ΔGm ratios of 87% or more. ΔG/ΔGm ratios were taken on the assumption that the members of the miRNA of one family differ by generally no more than one to three nucleotides and, along with a miRNA length of 22 nt, the ΔG/ΔGm value was 96% (21 nt/22 nt = 96%) − 87% (19 nt/22 nt = 87%). With a larger difference in the number of mismatched nucleotides, the probability of two or more miRNAs binding in one site increases, despite the miRNA’s natural ability to interact selectively with the mRNA of the target gene. The MirTarget program identifies the positions of the BSs on the mRNA, beginning with the first nucleotide of the mRNA’s 5′UTR. The MirTarget program found hydrogen bonds between adenine (A) and uracil (U), guanine (G) and cytosine (C), G and U, and A and C. The distance between A and C was 1.04 nanometers; 1.03 nanometers between G and C, and A and U; and 1.02 nanometers between G and U (Leontis, Stombaugh & Westhof, 2002). The numbers of hydrogen bonds in the G-C, A-U, G-U and A-C interactions were found to be 3, 2, 1 and 1, respectively (Kool, 2001; Lemieux & Major, 2002; Leontis, Stombaugh & Westhof, 2002). The characteristics of the interaction between miRNA and mRNA reflect the intermolecular interactions of their molecules and were calculated for given parameters without their variation. Consequently, the results have no statistical scatter. Other factors that may have influenced these interactions have not been studied. Our article does not address the subject of changing the concentration ratio of miRNA and mRNA, because this aspect is of independent interest and is not part of the objectives of this work. For any other pathology, other candidate genes should be used, and other miRNA BSs should be determined.

The MirTarget program determines single miRNA BSs in mRNA, and miRNA BSs in clusters (arranged in series with overlapping of nucleotide sequences of the same or several miRNAs). In this study we hypothesized that miRNA BSs in mRNA are organized into clusters. The MirTarget program does not work directly with miRBase and NCBI databases. The searches for target genes from 17,508 human genes in a special format from NCBI, for the known miRNAs from miRBase, and for novel miRNAs from other sources will be available on request at mirtarget8@gmail.com.

Results

The adequate prediction of miRNA BSs in mRNA target genes is a key problem when studying the biological role of miRNA in the regulation of gene expression. We have developed a MirTarget program that predicts the BSs of miRNA using mRNA, thereby revealing new properties of miRNA. Before presenting the results, we will provide a few specific examples that demonstrate the features of the MirTarget program.

The schemes of miRNA nucleotide interaction with mRNA BSs are shown in Figs. S1S3. The following advantages of the MirTarget program are shown: (a) almost all miRNA nucleotides interact with mRNA; (b) the formation of non-canonical pairs G-U and A-C do not change the double-stranded arrangement of the miRNA complex with mRNA since the distances between G-U and A-C are equal to the distances between G-C and A-U; (c) the free energy of interaction is an important criterion for binding miRNA to mRNA; and (d) the localization of the miRNA BSs in 5′UTR, CDS and 3′UTR.

Several miRNAs were bound to the entire nucleotide sequence of mRNA of triple-negative BC subtype candidate genes (Fig. S1). For example, miR-5095, miR-5096, miR-619-5p, miR-1273g-3p, and miR-1273f with entire nucleotide sequences were bound to the mRNA of the ATM gene. MiR-5095, miR-1273e, miR-1273f were bound to the mRNA IL11 gene by all nucleotides. Similarly, miR-1273c and miR-1285-3p were bound to the mRNA of the STMN1 gene, and ID00436.3p-miR was bound with the mRNA of the SFN gene.

ID01810.3p-miR had BSs in 5′UTR of the mRNA CBL gene (Fig. S1). Of the 23 nucleotides in ID01810.3p-miR, only one nucleotide could not form hydrogen bonds with mRNAs, and the other nucleotides formed a double-stranded helical structure with mRNA. Three pairs of G-U and three pairs of A-C, each with one hydrogen bond, contributed to the preservation of this structure due to the stacking interactions between adjacent bases (Yakovchuk, Protozanova & Frank-Kamenetskii, 2006). The binding of ID01810.3p-miR to the mRNA of the CBL gene caused non-canonical pairs G-U and A-C to form, and there was no interaction between A and G in the second position. Despite this, the free energy of the interaction of ID01810.3p-miR with the mRNA of the CBL gene was 87% of the maximum. The interaction schemes of ID01321.5p-miR with mRNA RUNX1 gene, miR-3198 with mRNA CBL gene, miR-1273d with mRNA IL11 gene, and miR-5585-3p with mRNA STMN1 gene are shown in Fig. S1. The free energy of interaction of these pairs of miRNAs and mRNAs was 87–98% of the maximum value of ΔGm (Table 1).

Table 1. Characteristics of miRNA interaction in the mRNA of BC subtype triple-negative.

Gene, RPKM miRNA Start of binding site, nt ΔG, kJ/mole ΔG/ΔGm, % Length, nt
CBL ID03332.3p-miR (4) 16 ÷ 25 −134 ÷−140 90 ÷ 94 24
3.9 ID01310.3p-miR (4) 17 ÷ 26 −121 92 22
ID02761.3p-miR 28 −138 93 24
miR-1908-3p 30 −121 92 21
ID00278.3p-miR 32 −125 91 23
ID02430.3p-miR 34 −110 98 18
MMP2 ID00278.3p-miR 110 −123 89 23
192.4 ID01310.3p-miR 113 −121 92 22
ID03037.3p-miR 115 −121 90 22
ID03345.5p-miR 124 −127 90 24
ID03368.3p-miR 125 −117 89 23
RAB5A ID02930.3p-miR 184 −132 89 24
16.1 ID03445.3p-miR 189 −127 90 24
ID01859.5p-miR 191 −121 89 23
ID01804.3p-miR 325 −140 88 25
ID03367.5p-miR 328 −121 97 20
ID00061.3p-miR 334 −127 92 22
ATM** ID03006.5p-miR 9,778 −121 89 24
3.9 miR-5095 9,787 −108 93 21
miR-619-5p 9,793 −119 98 22
miR-1273a 11,054 −119 90 25
miR-1273g-3p 11,076 −113 96 21
ID00367.5p-miR 11,069 −110 90 22
CBL** miR-1273a 7,727 −117 89 25
miR-1273g-3p 7,749 −115 98 21
3.9 ID01838.5p-miR 7,728 −117 93 24
IL11** miR-1273f 1,466 −102 98 19
0.1 miR-1273d 1,467 −121 89 25
miR-1273e 1,476 −113 96 22
ID01404.5p-miR 1,470 −113 91 23
RUNX1** miR-466 (2) 5,456 ÷ 5,460 −106 ÷ -110 91 ÷ 95 23
9.0 ID01030.3p-miR (2) 5,454 ÷ 5,464 −108 ÷−113 89 ÷ 93 23
D00436.3p-miR 5,464 −108 93 23
SFN** miR-6089 826 −129 87 24
9.4 ID01774.5p-miR 835 −129 90 23
miR-6846-5p 839 −113 91 22
ID00790.3p-miR 1,179 −104 89 23
ID02868.3p-miR 1,188 −113 90 23
miR-466 (6) 1,190 ÷ 1,200 −106 91 23
ID01030.3p-miR (6) 1,190 ÷ 1,200 −108 89 23
ID00436.3p-miR (7) 1,190 ÷ 1,202 −104 89 23
ID01727.5p-miR (2) 1,203 ÷ 1,205 −104 ÷−106 89 ÷ 91 23
ID02882.3p-miR 1,210 −108 91 21
STMN1** miR-1273a 1,729 −115 87 25
miR-1273g-3p 1,751 −108 93 21
ID00367.5p-miR 1,744 −113 91 22
6.6 ID03011.5p-miR 1,730 −106 91 22

Notes.

Genes without *—miRNA binding sites are in the 5′UTR, genes with *—miRNA binding sites are in the CDS, **—miRNA binding sites are in the 3′UTR; values in parentheses indicate the number of binding sites; ÷—the change of the parameter in the interval. Different repeating clusters of miRNA binding sites in different genes are coloured.

With the mRNA of luminal A and B BC subtype candidate genes, several miRNAs of the entire nucleotide sequences have been associated (Fig. S2). For example, ID01403.5p-miR and ID02428.3p-miR were bound to the mRNA HMGA2 gene. ID03332.3p-miR bound to the mRNA FOXA1 gene, and ID01593.5p-miR was fully complementarily bound to the mRNA ANGPTL4 gene.

MiR-3960, miR-7111-3p and ID01352.3p-miR were bound to the mRNA MAZ gene by all nucleotides (Fig. S3). MiR-877-3p was bound by all nucleotides to the mRNA of NISCH and MAZ genes, and ID00436.3p-miRwas bound to the mRNA of the CDK6 gene.

Subtype triple-negative breast cancer

The CBL gene is a target for six miRNAs, two of which have four BSs (Table 1). A cluster of 12 BSs for six miRNAs was located from 16 nt to 55 nt. All BSs for miRNAs had a total length of 270 nt. The cluster size was 40 nt, with a length of 142 nt for 5′UTR of the mRNA CBL gene, so there was a clear need for cluster organization of miRNA BSs. The BSs were compacted 6.8 times. The average free energy of interaction between the six miRNAs with the mRNA of the CBL gene was −127 kJ/mole.

The results of the supposed interactions of six miRNAs with the mRNA CBL gene can be represented as a diagram showing the location of the miRNA BSs relative to the mRNA cluster (Fig. 1). A feature of ID03332.3p-miR is the starting location of their repeating BSs across three nucleotides. This miRNA interacts with mRNA by displacing its BSs, coinciding with the open reading frame of the mRNA CBL gene. The schemes of interaction among these 12 miRNAs with the mRNA of the CBL gene are shown in Fig. 2. It can be seen from these schemes that the interaction between non-canonical pairs A-C and G-U increases the stability of the binding of miRNA to mRNA. From the data presented (Fig. 1) it can be seen that no more than one miRNA can bind with a cluster, which causes competition between the miRNAs to bind to the mRNA of a target gene. Some genes expressed in the mammary gland with an RPKM value of less than 10 contain repeats of nucleotides that are targeted by several miRNAs. In the mRNA CBL gene, which has a RPKM value of 3.9, four BSs were identified for ID03332.3p-miR and ID01310.3p-miR in a cluster located at 5′UTR from 16 nt to 54 nt (Table 1). Another example of a target gene for miRNA with nucleotide repeats in 3′UTR is the SFN gene with an RPKM value of 9.4 (Table 1). miR-466, ID01030.3.3p-miR and ID00436.3p-miR each had six BSs in the cluster from 1,190 nt to 1,214 nt.

Figure 1. Location of nucleotide sequences of miRNA binding sites cluster in mRNA CBL gene.

Figure 1

Figure 2. Schemes of interactions of miRNAs with mRNA of CBL gene in cluster of binding sites.

Figure 2

miRNA; the miRNA region; start of binding site (nt); the free energy, ΔG (kJ/mole); the ΔG/ΔGm (%); length of miRNA (nt). The upper and lower nucleotide sequences of mRNA and miRNA, respectively. The nucleotides of non-canonical pairs G–U and A–C highlighted in bold type.

Five miRNAs with overlapping BSs were found in the 5′UTR of the mRNA MMP2 gene with a cluster length of 39 nt. The total length of miRNA was 114 nt, which is 2.9 times greater than the total length of a cluster. The average free energy of interaction among the five miRNAs with the mRNA of MMP2 gene was −122 kJ/mole.

The RAB5A gene was a target for six miRNAs, and their BSs were formed into two clusters (Table 1). The cluster length of BSs for ID02930.3p-miR, ID03445.3p-miR, and ID01859.5p-miR located from 184 nt to 214 nt was 31 nt. The total length of the BSs of these miRNAs, arranged in succession, was 71 nt. Due to the overlapping of nucleotide sequences of the BSs of these miRNAs, the total length of the BSs was 2.3 times lower. However, at the same time, only one miRNA can interact with mRNA in the 31 nt segment. Thus, there is a competition between the three miRNAs to bind to the mRNA of the target gene. It is more likely that miRNA will bind with a greater free energy of interaction with mRNA at equal concentrations, or miRNA will be present in greater concentrations at an equal free energy of interaction with mRNA. The second cluster of miRNA BSs was located from 325 nt to 356 nt. The total length of miRNA BSs was 2.1 times the length of the cluster. The average free energy of interaction of the six miRNAs with the mRNA of RAB5A was −128 kJ/mole.

There were six miRNA BSs that formed two clusters of BSs in the mRNA of the ATM gene (Table 1). The total miRNA lengths for the first and second cluster were 67 and 68 nt, respectively. The decrease in the total length of the miRNA BSs at the overlap of their nucleotide sequence clusters was 1.6–1.8 times. The average free energy of interaction among the six miRNAs with the mRNA of ATM gene was −115 kJ/mole.

The cluster of BSs in the mRNA of the IL11 gene was located from 1466 nt to 1498 nt with a length of 31 nt. The sum of the lengths of BSs was 2.9 times the length of the cluster.

The BS clusters for three miRNAs were identified in 3′UTR of mRNA RUNX1 and CBL genes. Compacting the length of the BSs of miRNAs created competition between them for the BS in mRNA. The average free energy of the interactions between miRNA and mRNA in CBL and RUNX1 gene clusters were −116 kJ/mole and −109 kJ/mole, respectively.

There were two clusters of BSs for three miRNAs from 826 nt to 861 nt, and another cluster from 1,179 nt to 1,231 nt in 3′UTR of the mRNA SFN gene. The sum of the lengths of all miRNA BSs of the two clusters was 619 nt. Due to the clustering of BSs of these miRNAs, the actual BS was only 89 nt long, which is seven times less than the length of 3′UTR of the mRNA SFN gene, which is 498 nt. The average free energy of miRNA binding at 27 sites was −108 kJ/mole.

The STMN1 gene was the target of four miRNAs, its BSs in 3′UTR were 43 nt, while the total miRNA length was 90 nt. The average free energy of miRNA binding at four sites was −110 kJ/mole.

The free energy value was higher than −125 kJ/mole for the interactions among ID03332.3p-miR, ID02430.3p-miR, ID02761.3p-miR, ID00278.3p-miR, ID03345.5p-miR, ID02930.3p-miR, ID03445.3p-miR, ID01804.3p-miR, ID00061.3p-miR, ID03006.5p-miR, miR-1273d, miR-6089 and ID01774.5p-miR with the mRNAs of CBL, MMP2, RAB5A, ATM, IL11 and SFN genes.

Subtype luminal A and B breast cancer

Eighteen miRNA BSs with overlapping nucleotide sequences were identified in 5′UTR of the mRNA of the FOXA1 gene (Table 2). Twenty BSs formed a cluster with a length of 52 nt, spanning from 99 nt to 151 nt. The total length of all 20 BSs was 447 nt, which was longer than 5′UTR with a length of 312 nt. Since the cluster length was 52 nt, only two miRNAs could be bound simultaneously, and other miRNAs did not affect the expression of the FOXA1 gene.

Table 2. Characteristics of miRNAs interaction in mRNA of BC subtype luminal A and B.

Gene, RPKM miRNA Start of binding site, nt ΔG, kJ/mole ΔG/ΔGm, % Length, nt
FOXA1 ID00297.5p-miR 99 −123 89 24
10.2 ID02106.3p-miR 110 −123 89 23
ID00252.5p-miR 111 −140 94 24
ID02769.5p-miR 112 −127 92 22
ID01099.5p-miR 116 −108 100 17
ID01190.5p-miR 118 −108 100 17
ID00296.3p-miR 115 −140 89 25
ID01641.3p-miR 122 −134 90 24
ID01403.5p-miR 120 −123 91 23
ID00061.3p-miR 127 −129 94 22
ID03367.5p-miR (2) 121 ÷ 122 −117 93 20
miR-3960 120 −115 92 20
ID00071.3p-miR (2) 118 ÷ 121 −117 ÷−121 93 ÷ 97 20
ID02457.3p-miR 118 −108 100 17
ID02595.5p-miR 118 −115 92 20
ID01702.3p-miR 120 −140 89 25
ID00457.3p-miR 124 −123 91 22
ID02499.3p-miR (2) 127 ÷ 130 −119 ÷−121 92 ÷ 93 21
HMGA2 miR-6756-5p 529 −117 87 23
0.0 ID01737.3p-miR 539 −119 93 21
ID01041.5p-miR (2) 541 ÷ 544 −129 ÷−134 88 ÷ 91 24
ID00089.3p-miR 542 −125 91 22
ID01323.3p-miR 542 −117 95 20
ID02296.5p-miR 542 −115 93 20
ID0296.3p-miR 544 −146 93 25
ID01641.3p-miR 544 −142 96 24
ID01403.5p-miR 547 −119 88 23
ID00061.3p-miR 550 −132 95 22
ID03367.5p-miR 550 −115 92 20
miR-3960 549 −117 93 20
miR-4739 573 −123 87 25
ID00425.5p-miR 575 −121 88 24
ID00564.5p-miR 585 −110 90 22
ITGB1* ID02187.5p-miR 91 −127 92 23
63.6 miR-4787-5p 92 −123 92 22
ID00457.3p-miR 95 −123 91 22
ID02770.5p-miR 98 −117 93 20
ID01184.3p-miR 101 −117 93 20
HMGA2** ID01970.3p-miR 1,255 −113 90 23
0.0 ID00849.3p-miR (2) 1,261 ÷ 1,268 −117 90 22
ID01545.3p-miR 1,275 −115 95 21
SMAD3** miR-4690-5p 2,066 −115 92 22
ID02822.5p-miR 2,070 −127 91 23
ID00978.5p-miR 2,072 −119 90 22
miR-6089 (2) 2,073 ÷ 2,078 −132 ÷−136 89 ÷ 91 24
ID01382.3p-miR 2,075 −113 93 20
miR-3620-5p (2) 2,069 ÷ 2,074 −117 ÷−115 87 ÷ 89 22
SOX4** ID01839.3p-miR 2,994 −123 89 23
13.2 ID01282.3p-miR 3,000 −125 95 23
ID03445.3p-miR 3,000 −127 90 24
ID00101.3p-miR 3,001 −115 92 22
TGFB1** ID03306.3p-miR 2,060 −123 94 21
19.5 miR-6089 (4) 2,060 ÷ 2,095 −132 ÷−136 89 ÷ 91 24
ID01382.3p-miR 2,062 −113 93 20
miR-3620-5p 2,086 −115 87 22
ID03208.5p-miR 2,066 −125 88 24
ID00978.5p-miR 2,089 −119 90 22
ID00296.3p-miR 2,093 −140 89 25

Notes.

Genes without *—miRNA binding sites are in the 5′UTR, genes with *—miRNA binding sites are in the CDS, **—miRNA binding sites are in the 3′UTR; values in parentheses indicate the number of binding sites; ÷—the change of the parameter in the interval. Different repeating clusters of miRNA binding sites in different genes are coloured.

The formation of a cluster of BSs for the FOXA1 gene in 5′UTR indicated this gene’s capability for compaction, which causes competition among miRNA for the BS. Despite the fact that ID01099.5p-miR, ID01190.5p-miR and ID02457.3p-miR are fully complementary to the mRNA gene, they had a free energy interaction of −108 kJ/mole, which is significantly less than that of the other miRNAs. At equal concentrations of all miRNAs, ID00252.5p-miR, ID00296.3p-miR and ID01702.3p-miR had ΔG values of −140 kJ/mole because of their advantage in binding to the mRNA of the FOXA1 gene. The average free energy of miRNA binding, without the three miRNAs with a length of 17 nt, was −126 kJ/mole, which is characteristic of miRNA binding in 5′UTR.

BSs of 15 miRNAs were in 5′UTR of the HMGA2 mRNA cluster from 529 nt to 607 nt. The total length of BSs was 4.6 times greater than the cluster length. ID00296.3p-miR and ID00296.3p-miR had ΔG values of −142 kJ/mole and −146 kJ/mole, respectively.

The ITGB1 gene had no 5′UTR, but a cluster for five miRNA BSs was located from 91 nt to 121 nt in the beginning of CDS with a length of 31 nt, which is 3.5 times less than the sum of the lengths of five miRNAs.

For the HMGA2 gene, there was a cluster with a length of 41 nt for four BSs, with the BS total length of 88 nt.

Apparently, BSs compaction is associated not only with a decrease in the length of the gene, but also with increased competition between miRNAs. Take for example, the cluster of eight BSs with 3′UTR of the mRNA SMAD3 gene with a length of 35 nt. Only one miRNA can be bound in a cluster. At equal concentrations of all six miRNAs, ID02822.5p-miR and miR-6089, with free interaction energy of −127 kJ/mole to −136 kJ/mole, would have an advantage in binding to the cluster.

The 3′UTR of the mRNA SOX4 gene had four miRNA BSs organized in a cluster of 29 nt. ID01282.3p-miR and ID03445.3p-miR bound to mRNA had ΔG values of −125 kJ/mole and −127 kJ/mole, respectively.

The mRNAs of the TGFB1 gene had a BS cluster for seven miRNAs with a length of 60 nt. The length of 3′UTR was 146 nt with 10 miRNA BSs equal to 230 nt, compacting the BS 4.8 times.

Figure S2 shows the schemes of interaction among some miRNAs with mRNA of several candidate genes of the luminal A and B subtypes. The presented schemes clearly show the advantage of the MirTarget program in predicting the miRNA BSs. For example, ID03367.5p-miR formed a non-canonical G-U pair in the mRNA FOXA1 gene. However, ID03367.5p-miR was able to bind to 19 nucleotides of mRNA and the free energy interaction was 93% of the maximum value. The ID02542.5p-miR interacted with 23 nucleotides of the mRNA FOXA1 gene, but had only one unpaired nucleotide. Similar interactions between the miRNAs and their target genes are valid for the following pairs: ID00101.3p-miR and the HMGA2 gene, ID00849.3p-miR and the HMGA2 gene, miR-4507-3p and the SMAD3 gene, miR-937-5p and the TGFB1 gene, miR-937-5p and the SMAD3 gene, and ID01403.5p-miR and the HMGA2 gene.

Subtype HER2 breast cancer

Fifteen miRNAs were bound in 5′UTR mRNAs of three candidate genes of the breast cancer subtype HER2 (Table 3). The mRNA of the EPOR gene had three miRNA BSs, with overlapping nucleotide sequences. Three BSs of ID01633.3p-miR, ID01599.3p-miR and ID01626.3p-miR comprised a 26 nt cluster located in 5′UTR of the mRNA EPOR gene. Without overlapping sites, the length of three miRNAs would be 67 nt, which is half of the 135 nt length of 5′UTR. Consequently, the compacting of miRNA BSs is useful in reducing the proportion of BSs by 2.6 times in 5′UTR of the mRNA EPOR gene.

Table 3. Characteristics of miRNA interaction in mRNA genes of BC subtype HER2.

Gene, RPKM miRNA Start of binding site, nt ΔG, kJ/mole ΔG/ΔGm, % Length, nt
EPOR ID01633.3p-miR 77 −108 91 21
8.1 ID01599.3p-miR 79 −119 89 23
ID01626.3p-miR 80 −129 90 23
MAZ ID00968.3p-miR 16 −117 93 20
9.5 ID01476.3p-miR 16 −134 91 23
miR-1470 18 −123 97 21
ID00620.3p-miR 27 −127 91 23
miR-6850-5p 92 −115 87 22
miR-4466 107 −110 98 18
miR-762 111 −123 91 22
D00915.3p-miR 112 −127 88 24
ID02979.5p-miR 114 −121 92 22
NISCH ID03445.3p-miR 31 −125 88 24
32.2 ID01560.3p-miR 38 −123 89 23
ID03119.5p-miR 41 −125 88 24
MAPK3* ID00149.3p-miR 1,144 −117 93 22
32.6 ID01748.3p-miR 1,144 −110 91 21
miR-6805-3p 1,145 −117 87 23
MAZ* miR-6729-5p 361 −115 87 22
9.5 ID02623.3p-miR 363 −125 89 23
ID02460.5p-miR 372 −119 92 22
miR-2861 375 −110 95 19
ID02294.5p-miR (3) 457 ÷ 469 −134 ÷−138 91 ÷ 94 24
ID02986.5p-miR 459 −119 93 21
ID01819.5p-miR 461 −125 87 25
ID01804.3p-miR (2) 464 ÷ 467 −140 88 25
ID02064.5p-miR 489 −121 92 21
ID02538.3p-miR 489 −125 94 22
ID00296.3p-miR 500 −138 88 25
ID01641.3p-miR 506 −132 89 24
miR-3960 505 −119 95 20
miR-4706 605 −123 87 25
ID01705.3p-miR 608 −117 92 21
ID01641.3p-miR 608 −134 90 24
miR-3960 612 −117 93 20
ID01768.3p-miR 893 −113 90 22
ID01911.5p-miR 900 −123 89 23
ID00849.3p-miR 901 −125 97 22
BRCA2** ID00112.5p-miR 10,722 −102 91 21
0.1 ID02744.3p-miR 10,738 −104 92 22
miR-619-5p 10,746 −117 96 22
CDK6** miR-548h-3p 1,677 −104 91 23
2.2 miR-548z 1,677 −104 91 23
miR-548aq-3p 1,678 −102 94 22
miR-548az-3p 1,678 −98 94 21
ID03264.3p-miR 1,678 −98 90 22
miR-466 (10) 1,908 ÷ 1,926 −104 ÷−108 90 ÷ 93 23
ID01030.3p-miR (7) 1,900 ÷ 1,918 −108 ÷−115 89 ÷ 95 23
ID00436.3p-miR (9) 1,896 ÷ 1,920 −104 ÷−106 89 ÷ 91 23
ID02513.5p-miR 1,901 −102 91 22

Notes.

Genes without *—miRNA binding sites are in the 5′UTR, genes with *—miRNA binding sites are in the CDS, **—miRNA binding sites are in the 3′UTR; values in parentheses indicate the number of binding sites; ÷—the change of the parameter in the interval. Different repeating clusters of miRNA binding sites in different genes are coloured.

In the mRNA of the MAZ gene, the BSs of ID00968.3p-miR, ID01476.3p-miR, miR-1470, and ID00620.3p-miR were located in a cluster with a length of 34 nt. The total length of the four miRNAs was equal to 87 nt. Another cluster in MAZ mRNA with a length of 44 nt was formed by miR-6850-5p, miR-4466, miR-762, ID00915.3p-miR and ID02979.5p-miR BSs. Both clusters occupied only 78 nt, and the total length of BSs of nine miRNAs was 196 nt.

In the mRNA of the NISCH gene, the BSs of ID03445.3p-miR, ID01560.3p-miR and ID03119.5p-miR formed a cluster with a length of 35 nt. With cluster formation, the length of these BSs was 71 nt, i.e., 52% of the length of 5′UTR.

There were 24 miRNAs for which the mRNA was targeted in CDS. MAPK3 gene was a target of three miRNAs, the BSs of which were located in a cluster with a length of 26 nt. The mRNA of the MAZ gene had miRNA BSs with nucleotide sequences overlapping into four different clusters (Table 3). The first cluster with a length of 33 nt included BSs of miR-6729-5p, ID02623.3p-miR, ID02460.5p-miR and miR-2861. Nucleotide sequences of BS clusters encoded the oligopeptide APAPPPTPQA, which was conservative in orthologous proteins MAZ of H. sapiens, P. abelii, P. troglodytes, and C. sabaesus (Fig. 3A). The second cluster was located from 457 nt to 530 nt. The total length of all BSs of miRNAs of this cluster was 302 nt. This length required BS compaction since all nucleotides participate in the coding of functionally important amino acids in CDS. Despite the long length of the cluster of nine miRNA BSs encoding the oligopeptide AAAAAAAAAAAAAVAAAPPAPAAA, the MAZ orthologs were conservative (Fig. 3B). The third cluster consisted of miR-4706, ID01641.3p-miR, ID01705.3p-miR, and miR-3960 BSs with a length of 30 nt. The cluster encoded the conservative oligopeptide APPASAAT (Fig. 3C). The fourth cluster, with a length of 30 nt, included BSs for three miRNAs. The encoded subcluster oligopeptide GAGGGGGEAG was also conservative (Fig. 3D).

Figure 3. Logo plots of variation of amino acids in the region of orthologous MAZ proteins.

Figure 3

Orthologous MAZ proteins containing: APAPPPTPQA oligopeptide (A), AAAAAAAAAAAAAVAAAPPAPAAA oligopeptide (B), APPASAAT oligopeptide (C), and GAGGGGGEAG oligopeptide (D) of Hsa, Pab, Ptr, Csa. Conservative oligopeptides are highlighted in blue.

All BSs for miRNAs that interacted with MAZ mRNA had a total length of 472 nt, which was approximately 33% of the total CDS length. Clustered BSs for miRNA occupied only 1,434 nt, 12% of CDS length. The MAZ gene was the most preferable target for miRNA, so monitoring its expression should be a priority.

Fifteen miRNAs were bound within the mRNA of candidate breast cancer subtype HER2 genes with a free energy of −125 kJ/mole or greater (Table 3). For example, ID01626.3p-miR had a competitive advantage over ID01633.3p-miR and ID01599.3p-miR for binding in the mRNA cluster EPOR. In two clusters of MAZ mRNA, ID01476.3p-miR and ID00915.3p-miR were predominantly bound. The translation of the mRNA MAZ gene will be significantly suppressed if ID02294.5p-miR (which has three BSs) is present, and ID01804.3p-miR and ID00296.3p-miR have sites with a free binding energy of −140 kJ/mole and −138 kJ/mole, respectively.

In 3′UTR of the mRNA BRCA2 gene, three miRNA BSs were identified with overlapping nucleotide sequences (Table 3). The CDK6 gene was a target for nine miRNAs. miR-548h-3p, miR-548z, miR-548aq-3p, miR-548az-3p, and ID03264.3p-miR formed a cluster from 1,677 nt to 1,699 nt. The mRNA of BRCA2 and CDK6 genes had BSs for miRNA in 3′UTR with a low free energy of binding: −98 kJ/mole to −117 kJ/mole. In the 3′UTR of the mRNA CDK6 gene with an RPKM value of 2.2, there were 10 BSs of miR-466, nine BSs of ID00436.3p-miR, and seven BSs of ID01030.3p-miR forming a cluster from 1,896 nt to 1,948 nt (Table 3). Multiple BSs for these miRNAs allowed them to bind with mRNA and significantly increased the probability of translation inhibition of the mRNA CDK6 gene.

Compacting miRNA BSs is difficult to explain if its sole purpose is conserving the length of 3′UTR, since there are various reasons for compacting BSs. For example, the binding of one miRNA precludes other miRNAs binding with that site. If this miRNA is a signal of the host gene (gene encoding miRNA), the target gene will not perceive this signal. Specifically, there is competition between different miRNAs for the BS, and for the ability to regulate the expression of the target gene.

It should be noted that most miRNA BSs were located at the beginning of 5′UTR and CDS mRNA regions of the MAZ gene (Table 3). This localization of miRNA BSs allows protein synthesis to be ended earlier in the case of the formation of abortive proteins. For example, the first three clusters of miRNA BSs were located in CDS of the mRNA MAZ gene. All BSs of nine miRNAs in 5′UTR of mRNA MAZ were located between 16 nt and 114 nt of the 168 nt length of 5′UTR.

The miRNA BSs in 3′UTR of mRNA BRCA2 and CDK6 genes were also located at the beginning of 3′UTR (Table 3).

Figure S3 shows the schemes of interaction of miRNAs with mRNAs of candidate genes of the subtype HER2. Several miRNAs and their target genes (ID02998.3p-miR and MAZ gene, miR-5008-5p and MAZ gene, ID02499.3p-miR and MAZ gene, miR-6805-3p and MAPK3 gene, miR-3960 and MAZ gene, miR-877-3p, miR-7111-3p, and ID01352.3p-miR) had BSs in the same region of the mRNA MAZ gene from 2,273 nt to 2,774 nt. All miRNA nucleotides formed hydrogen bonds with this region of mRNA.

After the discovery of clusters of miRNA BSs with mRNA of candidate genes of breast cancer subtypes, the question arises as to how stable these structural forms are. It is known that some miRNAs arose in early stages of evolution and have been stable for tens of millions of years of species divergence (Kondybayeva et al., 2018). Other miRNA associations with mRNA have appeared recently, and they have not been observed even in closely related species. Taking this into consideration, we checked the variability of nucleotide sequences of BSs in the clusters we identified. The analysis results of nucleotide sequences of clusters in mRNA candidate breast cancer subtypes are given in Tables S3S5. The data obtained show that in most cases the nucleotide sequences of clusters are identical. Observed differences in single nucleotides show slight changes in the degree of interaction between miRNA and BSs. Consequently, established bindings between miRNAs and BSs organized in clusters are stable in genomes of studied objects which have diverged over millions of years. Evolutionary conservatism allows options among adequate animal models for studying associations between miRNAs and mRNAs.

Discussion

Dysregulation of gene expression by miRNAs is one of the causes of oncogenesis (Adhami et al., 2018), and studies about the participation of miRNAs in oncogenesis testifies to their important role in this process (Persson et al., 2011). Many studies have been devoted to the role of miRNA in various diseases, including triple-negative BC (Bar et al., 2017; Buschmann et al., 2018; Yao et al., 2018), luminal A and B subtypes of BC (Aure et al., 2017; Hannafon et al., 2016; Wang & Luo, 2015) and the HER2 subtype of BC (Halvorsen et al., 2017; Patel et al., 2016; Wang & Lin, 2013). However, there have been few reliably established associations between miRNA and target genes. In this article, we identified associations of the miRNAs with their target genes that may be responsible for the development of breast cancer, taking into account its subtypes. The selectivity of miRNA and mRNA interaction, as well as the facts of preservation of the entire miRNA nucleotide sequence and the corresponding BSs in the mRNA of target genes, demonstrate the stability of these interactions over tens of millions of years of evolution (Yurikova et al., 2019). We applied new bioinformatics approaches to the assessment of these relationships, which allowed us to reveal important characteristics of the binding between miRNAs and target genes (Tables 13). Previously experimentally established miRNA BSs using the mRNA of target RTL1 genes (Davis et al., 2005) were verified using the MirTarget program. The RTL1 gene is located on the antisense sequence for 10 miRNA, and participates in oncogenesis through them. For example, miR-127-5p can suppress the expression of a tumor suppressor gene (Wang et al., 2011a), miR-136-5p can regulate the expression of CLDN15 (Yurikova et al., 2019), ENAH genes are involved in tumor invasion (Forse et al., 2015; Takehara et al., 2009), and miR-432-3p can affect the gene IL2RB involved in the development of breast cancer (García-Tuñón et al., 2004). With the MirTarget program, we confirmed the seven experimentally established BSs for miR-127, miR-136, miR-431, miR-433-3p/5p, and miR-434-3p/5p with the mRNA of the RTL1 gene, and we predicted another three BSs for miRNAs (Davis et al., 2005). All 10 miRNA BSs were located in the CDS of the mRNA gene, and the nucleotide sequences of miRNA and mRNA were fully complementary. Note that the nucleotide sequences miR-127-5p and miR-127-3p were conservative in species that had diverted tens of millions of years ago, according to miRBase (Yurikova et al., 2019). Using the MirTarget program, we predicted miRNA BSs in the CDS, 5′UTR and 3′UTR of many genes (Atambayeva et al., 2017; Ivashchenko et al., 2016; Ivashchenko et al., 2014a; Ivashchenko et al., 2014b; Ivashchenko, Issabekova & Berillo, 2013). The nucleotide sequences of miRNA and their BSs have been conserved in the mRNA genes of animal and plant organisms over tens of millions of years of evolution (Bari, Orazova & Ivashchenko, 2013; Ivashchenko et al., 2016; Ivashchenko et al., 2014a; Ivashchenko et al., 2014b; Ivashchenko, Issabekova & Berillo, 2013).

The MirTarget program detects BS organization with overlapping nucleotide sequences. The organization of BSs into clusters has two consequences: (a) BSs are compacted to reduce their share in the total length of mRNA; (b) competition is created among miRNAs to bind to mRNA, taking into account the free energy of miRNA interaction with mRNA.

The competition between miRNA complicated our interpretation of the expected effects of changing the miRNA concentration. In diseases, the concentration of miRNA can increase and decrease dozens of times (Lu et al., 2016; Yang, Sui & Liang, 2017). For example, a decrease in the concentration of one miRNA may not cause any effect, since other miRNAs will inhibit protein translation. In most cases, the binding of miRNA with mRNA is unlikely to lead to a complete suppression of translation, such as with a fully complementary interaction of miRNA with mRNA (Davis et al., 2005). Even a few miRNAs will not cause a complete suppression of translation if their concentration is less than the concentration of mRNA.

It has been found that some miRNAs may bind to the mRNA of more than one candidate gene of different subtypes. For example, ID03445.3p-miR may interact with the mRNA of the NISCH gene of the HER2 subtype, mRNA of the RAB5A gene of the triple-negative subtype, and mRNA of the SOX4 gene of luminal A and B subtypes (Tables 13). Additionally, ID00061.3p-miR can bind to mRNA of the RAB5A gene of the triple-negative subtype and mRNA of the FOXA1 gene of luminal A and B subtypes (Tables 1 and 2). ID01641.3p-miR can interact with mRNA of FOXA1, HMGA2 genes of luminal A and B subtypes, and with mRNA of the MAZ gene of the HER2 subtype (Tables 2 and 3). miR-466 could bind to mRNA of RUNX1, SFN and CDK6 genes (Tables 1 and 3). One miRNA can interact with mRNA of two or more candidate genes of the same subtype. For example, miR-6089 can bind to mRNA of SMAD3 and TGFB1 genes when it has two and four consecutive sites (Table 2), and to mRNA of the SFN gene with one BS (Table 1). The ID00367.5p-miR and miR-1273g-3p BSs were located through seven nucleotides in mRNA of the ATM gene and STMN1 gene (Table 1). BSs of these miRNAs were part of corresponding clusters.

A distinctive feature of candidate genes of the triple-negative subtype is the presence of several genes of miR-1273 family BSs in mRNA (Table 1). The mRNA of the IL11 gene in the cluster included BSs of miR-1273d, miR-1273e and miR-1273f. The mRNA genes of ATM, CBL, and STMN1 included BSs of miR-1273a and miR-1273g-3p, with a distance of 22 nt between the origins of their BSs. Characteristics of the interactions of the miR-1273 family with candidate genes of the triple-negative subtype are not random. mRNA of candidate genes of luminal A and B, and HER2 subtypes lack the BSs of the miR-1273 family (Tables 2 and 3). We predicted several multiple BSs for a single miRNA. For example, miR-466 had two BSs in mRNA of the RUNX1 gene, six BSs in mRNA of the SFN gene, and 10 BSs in mRNA of the CDK6 gene (Tables 1 and 3). BSs of ID01030.3p-miR and ID00436.3p-miR were included in clusters of mRNA BSs of ATM and SFN genes (Table 1). The mRNA of the SFN gene had six BSs with ID01030.3p-miR and ID00436.3p-miR. It is known that single nucleotide, dinucleotide, and trinucleotide repeats are found in mRNA genes, and which nucleotide repeats are targets for miRNA have been shown (Kondybayeva et al., 2018; Niyazova et al., 2015). The position of BSs in the same cluster suggests competition between miRNA to bind to mRNA of the target gene. Competition among miRNAs for BSs also occurs when they are bound to mRNA of different genes if they are expressed both in a single cell and in different cells of the body, since miRNA is transported through the body with blood (Hannafon et al., 2016; Lagendijk et al., 2018; Zhang et al., 2017). It is necessary to take into account the concentration of miRNA and mRNA to explain the effectiveness of their interaction.

Some miRNAs can bind with high free energy to mRNA of targets genes of different subtypes: ID.01804.3p-miR and RAB5A, MAZ (−140 kJ/mole); ID.00252.5p-miR and FOXA1 (−140 kJ/mole); ID.00296.3p-miR and FOXA1, HMGA2 (−146 kJ/mole); and ID.01641.3p-miR and HMGA2 (−142 kJ/mole) (Tables 13). Such associations of miRNA and target genes can be used as markers of two BC subtypes, since the expression of these genes will be significantly suppressed by the corresponding miRNA. Simultaneously while controlling the expression of these miRNA and gene associations, it is necessary to control the expression of specific associations for each subtype. For example, such associations may be for ID.03332.3p-miR, ID.02761.3p-miR and the CBL gene; ID.02930.3p-miR, ID.01804.3p-miR and the RAB5A gene for triple-negative subtype (Table 1); ID.01702.3p-miR and the FOXA1 gene for the luminal subtype A and B (Table 2); or ID.1476.3p-miR, ID.02294.5p-miR and the MAZ gene for the subtype HER2 (Table 3).

Tables 13 provide information (RPKM) on the normal expression of candidate genes in the mammary gland. The most highly expressed genes are MMP2 (Table 1), ITGB1 (Table 2), NISCH, and MAPK3 (Table 3). The mRNA of MMP2 and ITGB1 genes contain clusters of BSs for five miRNAs, and the mRNA of NISCH and MAPK3 genes contain clusters for three miRNAs. Consequently, the expression of these candidate genes and miRNAs binding in respective clusters can be used to develop methods for diagnosing BC subtypes. The HMGA2 gene is not normally expressed (Table 2), but its mRNA has two binding clusters for 18 miRNAs, and some miRNAs can bind with high free energy to mRNA, suggesting the suppression of its possible expression. Several studies have shown that this gene can be expressed in tumor cells and its increased expression leads to the development of oncogenesis (Chen et al., 2019; Niu et al., 2019; Pearlman et al., 2019; Piscuoglio et al., 2012; Sun et al., 2014; Wang et al., 2011b).

For each of the BC subtypes, two or more miRNAs with binding sites in the same cluster and in several genes were detected; for example, identified BS clusters for miR-1273a and miR-1273g-3p in ATM, CBL and STMN1 genes of the triple-negative subtype (Table 1). For miR-466, ID.01030.3p-miR and ID.00436.3p-miR binding sites were found in clusters mRNA of RUNX1 and SFN genes of the triple-negative subtype. These two associations of miRNAs and candidate genes can serve as markers for the diagnosis of a triple-negative subtype. For miR-466, ID.01030.3p-miR and ID.00436.3p-miR binding sites were found in the cluster mRNA of CDK6 candidate gene of the HER2 subtype. Consequently, in addition to controlling the concentration of these three miRNAs, the control of the expression of target genes is necessary to establish the disease subtype.

The mRNA SMAD3 and TGFB1 genes of luminal A and B subtypes contain clusters of binding sites of miR-6089, ID.01382.3p-miR and miR-3620-5p, which justify the use of these associations between miRNAs and genes as markers of luminal A and B subtypes. However, the candidate SFN gene of the triple-negative subtype also contains an miR-6089 binding site. Therefore, in this case it is also necessary to control the expression of SFN gene to identify the disease subtype. The examples above show that for accurate labeling of disease subtypes, it is imperative to control the expression of miRNAs and target genes. The same examples show the inadequacy of diagnosing using one or several miRNAs with concentrations changing correlatively across different subtypes without controlling the influence of these miRNAs on target genes. The results of this work show the necessity for simultaneous quantitative control of the expression of many genes and miRNAs.

Our proposed use of the associations between miRNA and target genes should be analyzed, while taking into account the following factors: (a) miRNA and their target genes perform limited stages of key biological processes involved in the development of diseases; (b) these interactions between miRNA with mRNA have high free energy; (c) there is a greater number of miRNAs that bind to mRNA; and (d) included miRNAs have more target genes. Depending on circumstances, the adequacy and significance of the associations listed between miRNAs and mRNA may vary.

Conclusions

Using the associations between miRNAs and their targets genes has been identified as a method for identifying breast cancer subtypes. The clustering of miRNA BSs decreases the fraction of BSs with nucleotide sequences in mRNA. The cluster organization of miRNA BSs is mainly found in 5′UTR and 3′UTR. In the CDS, the share of miRNA BSs organized into clusters is less than that of single miRNA BSs. The cluster organization of miRNA BSs, together with the free energy of miRNA interaction with mRNA, causes competition between miRNAs to bind to mRNA. This phenomenon demonstrates the competitive relationship among miRNAs in the regulation of the expression of target genes. The number of miRNA BSs in clusters indicates the degree of dependence of the expression of target genes on the expression of other miRNA host genes. Our results show the necessity for simultaneous quantitative control of the expression of many genes and many miRNAs in the development of methods to diagnose studied breast cancer subtypes.

Supplemental Information

Figure S1. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer triple-negative subtype.
DOI: 10.7717/peerj.8049/supp-1
Figure S2. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer luminal A and B subtypes.
DOI: 10.7717/peerj.8049/supp-2
Figure S3. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer HER2 subtype.
DOI: 10.7717/peerj.8049/supp-3
Table S1. Candidate genes of subtypes of breast cancer, indicating sources of information on their participation in oncogenesis of breast cancer.
DOI: 10.7717/peerj.8049/supp-4
Table S2. Information on miRNAs interacted with genes of breast cancer and other cancer.
DOI: 10.7717/peerj.8049/supp-5
Table S3. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of triple-negative subtype.
DOI: 10.7717/peerj.8049/supp-6
Table S4. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of luminal A and B subtypes.
DOI: 10.7717/peerj.8049/supp-7
Table S5. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of HER2 subtype.
DOI: 10.7717/peerj.8049/supp-8

Funding Statement

The work was carried out with the financial support of the Ministry of Education and Science of the Republic of Kazakhstan within the framework of the grant No AP05132460. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Additional Information and Declarations

Competing Interests

There are no competing interests.

Author Contributions

Dana Aisina, Raigul Niyazova, Shara Atambayeva and Anatoliy Ivashchenko conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The nucleotide sequences of candidate genes (ID) of BC subtypes are available at NCBI. The accession numbers are in Table S1.

The nucleotide sequences of 2565 miRNAs from miRBase and 3707 miRNAs are available from: Novel primate- and tissue-specific microRNAs, Proceedings of the National Academy of Sciences Mar 2015, 112 (10) E1106–E1115; DOI: 10.1073/pnas.1420955112

Protein expression was found by the corresponding gene (ID) in the Human Protein Atlas. Reads Per Kilobase Million (RPKM) value is available in the Human Protein Atlas data (https://www.proteinatlas.org/ENSG00000150093-ITGB1/tissue/breast).

References

  • Adhami et al. (2018).Adhami M, Haghdoost AA, Sadeghi B, Malekpour AR. Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2018;25:198–205. doi: 10.1007/s12282-017-0814-8. [DOI] [PubMed] [Google Scholar]
  • Atambayeva et al. (2017).Atambayeva S, Niyazova R, Ivashchenko A, Pyrkova A, Pinsky I, Akimniyazova A, Labeit S. The binding sites of miR-619-5p in the mRNAs of human and orthologous genes. BMC Genomics. 2017;18:428. doi: 10.1186/s12864-017-3811-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Aure et al. (2017).Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK. Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Research. 2017;19:44. doi: 10.1186/s13058-017-0812-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bar et al. (2017).Bar I, Merhi A, Abdel-Sater F, Ben Addi A, Sollennita S, Canon JL, Delrée P. The MicroRNA miR-210 is expressed by cancer cells but also by the tumor microenvironment in triple-negative breast cancer. Journal of Histochemistry and Cytochemistry. 2017;65:335–346. doi: 10.1369/0022155417702849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Bari, Orazova & Ivashchenko (2013).Bari A, Orazova S, Ivashchenko A. miR156- and miR171-binding sites in the protein-coding sequences of several plant genes. BioMed Research International. 2013;2013:1–7. doi: 10.1155/2013/307145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Benson & Jatoi (2012).Benson JR, Jatoi I. The global breast cancer burden. Future Oncology. 2012;8:697–702. doi: 10.2217/fon.12.61. [DOI] [PubMed] [Google Scholar]
  • Biagioni et al. (2012).Biagioni F, Bossel BMN, Fontemaggi G, Canu V, Mori F, Antoniani B, Di Benedetto A, Santoro R, Germoni S, De Angelis F, Cambria A, Avraham R, Grasso G, Strano S, Muti P, Mottolese M, Yarden Y, Domany E, Blandino G. miR-10b*, a master inhibitor of the cell cycle, is down-regulated in human breast tumours. EMBO Molecular Medicine. 2012;4:1214–1229. doi: 10.1002/emmm.201201483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Blenkiron et al. (2007).Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology. 2007;8:R214. doi: 10.1186/gb-2007-8-10-r214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Buschmann et al. (2018).Buschmann D, González R, Kirchner B, Mazzone C, Pfaffl MW, Schelling G, Steinlein O, Reithmair M. Glucocorticoid receptor overexpression slightly shifts microRNA expression patterns in triple-negative breast cancer. International Journal of Oncology. 2018;52:1765–1776. doi: 10.3892/ijo.2018.4336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Chen et al. (2019).Chen X, Zeng K, Xu M, Liu X, Hu X, Xu T, He B, Pan Y, Sun H, Wang S. P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2. Cell Death & Disease. 2019;10:131. doi: 10.1038/s41419-018-1188-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Davis et al. (2005).Davis E, Caiment F, Tordoir X, Cavaillé J, Ferguson-Smith A, Cockett N, Georges M, Charlier C. RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 locus. Current Biology. 2005;15:743–749. doi: 10.1016/j.cub.2005.02.060. [DOI] [PubMed] [Google Scholar]
  • Enerly et al. (2011).Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLOS ONE. 2011;6:e16915. doi: 10.1371/journal.pone.0016915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Forse et al. (2015).Forse CL, Agarwal S, Pinnaduwage D, Gertler F, Condeelis JS, Lin J, Xue X, Johung K, Mulligan AM, Rohan TE, Bull SB, Andrulis IL. Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer. 2015;15:483. doi: 10.1186/s12885-015-1468-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • García-Tuñón et al. (2004).García-Tuñón I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Research. 2004;6:R1–R7. doi: 10.1186/bcr820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Halvorsen et al. (2017).Halvorsen AR, Helland A, Gromov P, Wielenga VT, Talman MM, Brunner N, Sandhu V, Børresen-Dale AL, Gromova I, Haakensen VD. Profiling of microRNAs in tumor interstitial fluid of breast tumors—a novel resource to identify biomarkers for prognostic classification and detection of cancer. Molecular Oncology. 2017;11:220–234. doi: 10.1002/1878-0261.12025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Hannafon et al. (2016).Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Research. 2016;18:90. doi: 10.1186/s13058-016-0753-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Huggett & O’Grady (2014).Huggett J, O’Grady J. Molecular diagnostics: current research and applications. Caister Academic Press; Poole: 2014. p. 248. [Google Scholar]
  • Ivashchenko et al. (2014b).Ivashchenko A, Berillo O, Pyrkova A, Niyazova R. Binding sites of miR-1273 family on the mRNA of target genes. Biomed Research International. 2014b;2014:e11. doi: 10.1155/2014/620530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Ivashchenko et al. (2014a).Ivashchenko A, Berillo O, Pyrkova A, Niyazova R, Sh Atambayeva. The properties of binding sites of miR-619-5p, miR-5095, miR-5096 and miR-5585-3p in the mRNAs of human genes. Biomed Research International. 2014a;2014:e8. doi: 10.1155/2014/720715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Ivashchenko, Issabekova & Berillo (2013).Ivashchenko A, Issabekova AS, Berillo OA. miR-1279, miR-548j, miR-548m, and miR-548d-5p binding sites in CDSs of paralogous and orthologous PTPN12, MSH6, and ZEB1 Genes. BioMed Research International. 2013;2013:902467. doi: 10.1155/2013/902467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Ivashchenko et al. (2016).Ivashchenko AT, Pyrkova AY, Niyazova RY, Alybayeva A, Baskakov K. Prediction of miRNA binding sites in mRNA. Bioinformation. 2016;12:237–240. doi: 10.6026/97320630012237. [DOI] [Google Scholar]
  • Jemal et al. (2010).Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiology, Biomarkers & Prevention. 2010;10:1893–1907. doi: 10.1158/1055-9965.EPI-10-0437. [DOI] [PubMed] [Google Scholar]
  • Kondybayeva et al. (2018).Kondybayeva AM, Akimniyazova AN, Kamenova SU, Ivashchenko AT. The characteristics of miRNA binding sites in mRNA of ZFHX3 gene and its orthologs. Vavilov Journal of Genetics and Breeding. 2018;22:438–444. doi: 10.18699/VJ18.380. [DOI] [Google Scholar]
  • Kool (2001).Kool ET. Hydrogen bonding, base stacking, and steric effects in DNA replication. Annual Review of Biophysics and Biomolecular Structure. 2001;30:1–22. doi: 10.1146/annurev.biophys.30.1.1. [DOI] [PubMed] [Google Scholar]
  • Kurozumi et al. (2017).Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J. In microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. Journal of Human Genetics. 2017;62:15–24. doi: 10.1038/jhg.2016.89. [DOI] [PubMed] [Google Scholar]
  • Lagendijk et al. (2018).Lagendijk M, Sadaatmand S, Koppert LB, Tilanus-Linthorst MMA, De Weerd V, Ramírez-Moreno R, Smid M, Sieuwerts AM, Martens JWM. MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer. Oncotarget. 2018;9:24335–24346. doi: 10.18632/oncotarget.25262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lee et al. (2013).Lee CH, Kuo WH, Lin CC, Oyang YJ, Huang HC, Juan HF. MicroRNA-regulated protein-protein interaction networks and their functions inbreast cancer. International Journal of Molecular Sciences. 2013;14:11560–11606. doi: 10.3390/ijms140611560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lemieux & Major (2002).Lemieux S, Major F. RNA canonical and non-canonical base pairing types: a recognition method and complete repertoire. Nucleic Acids Research. 2002;30:4250–4263. doi: 10.1093/nar/gkf540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Leontis, Stombaugh & Westhof (2002).Leontis NB, Stombaugh J, Westhof E. The non-Watson-Crick base pairs and their associated isostericity matrices. Nucleic Acids Research. 2002;30:3497–3531. doi: 10.1093/nar/gkf481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Londin et al. (2015).Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America. 2015;112:1106–1115. doi: 10.1073/pnas.1420955112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lowery et al. (2009).Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor andHER2/neu receptor status in breast cancer. Breast Cancer Research. 2009;11:R27. doi: 10.1186/bcr2257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Lu et al. (2016).Lu Y, Qin B, Hu H, Zhang J, Wang Y, Wang Q, Wang S. Integrative microRNA-gene expression network analysis in genetic hypercalciuric stone-forming rat kidney. PeerJ. 2016;4:e1884. doi: 10.7717/peerj.1884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Mattie et al. (2006).Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer. 2006;5:24. doi: 10.1186/1476-4598-5-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • McDermott et al. (2014).McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLOS ONE. 2014;9:e87032. doi: 10.1371/journal.pone.0087032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Mortazavi et al. (2008).Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nature Methods. 2008;5:621–628. doi: 10.1038/nmeth.1226. [DOI] [PubMed] [Google Scholar]
  • Nian et al. (2013).Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F, Wang D. miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncology Letters. 2013;6:359–366. doi: 10.3892/ol.2013.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Niu et al. (2019).Niu Y, Zhou H, Liu Y, Wang Y, Xie J, Feng C, An N. miR-16 regulates proliferation and apoptosis of pituitary adenoma cells by inhibiting HMGA2. Oncology Letters. 2019;17:2491–2497. doi: 10.3892/ol.2018.9872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Niyazova et al. (2015).Niyazova R, Berillo O, Sh Atambayeva, Pyrkova A, Alybayeva A, Ivashchenko A. miR-1322 binding sites in paralogous and orthologous genes. BioMed Research International. 2015;1:7. doi: 10.1155/2015/962637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Patel et al. (2016).Patel Y, Shah N, Lee JS, Markoutsa E, Jie C, Liu S, Botbyl R, Reisman D, Xu P, Chen H. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. Oncotarget. 2016;7:18295–18308. doi: 10.18632/oncotarget.7577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Pearlman et al. (2019).Pearlman A, Rahman M, Upadhyay K, Loke J, Ostrer H. Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions. PLOS ONE. 2019;14:e0211737. doi: 10.1371/journal.pone.0211737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Persson et al. (2011).Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, Loman N, Jonsson G, Naya H, Hoglund M, Borg A, Rovira C. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Research. 2011;71:78–86. doi: 10.1158/0008-5472.CAN-10-1869. [DOI] [PubMed] [Google Scholar]
  • Piasecka et al. (2018).Piasecka D, Braun M, Kordek R, Sadej R, Romanska H. MicroRNAs in regulation of triple-negative breast cancer progression. Journal of Cancer Research and Clinical Oncology. 2018;144:1401–1411. doi: 10.1007/s00432-018-2689-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Piscuoglio et al. (2012).Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A, Karamitopoulou E. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology. 2012;60:397–404. doi: 10.1111/j.1365-2559.2011.04121. [DOI] [PubMed] [Google Scholar]
  • Qian et al. (2012).Qian P, Banerjee A, Wu ZS, Zhang X, Wang H, Pandey V, Zhang WJ, Lv XF, Tan S, Lobie PE, Zhu T. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Research. 2012;72:6036–6050. doi: 10.1158/0008-5472.CAN-12-1507. [DOI] [PubMed] [Google Scholar]
  • Sun et al. (2014).Sun M, Gomes S, Chen P, Frankenberger CA, Sankarasharma D, Chung CH, Chada KK, Rosner MR. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2014;33:3528–3537. doi: 10.1038/onc.2013.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Sung et al. (2012).Sung H, Jeon S, Lee KM, Han S, Song M, Choi JY, Park SK, Yoo KY, Noh DY, Ahn SH, Kang D. Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. BMC Cancer. 2012;12:195. doi: 10.1186/1471-2407-12-195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Tahiri et al. (2014).Tahiri A, Leivonen SK, Lüders T, Steinfeld I, Ragle Aure M, Geisler J, Mäkelä R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN. Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis. 2014;35:76–85. doi: 10.1093/carcin/bgt333. [DOI] [PubMed] [Google Scholar]
  • Takehara et al. (2009).Takehara M, Nishimura T, Mima S, Hoshino T, Mizushima T. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biological and Pharmaceutical Bulletin. 2009;32:825–831. doi: 10.1248/bpb.32.825. [DOI] [PubMed] [Google Scholar]
  • Telonis et al. (2015).Telonis AG, Loher P, Jing Y, Londin E, Rigoutsos I. Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. Nucleic Acids Research. 2015;43:9158–9175. doi: 10.1093/nar/gkv922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wang et al. (2011a).Wang S, Huang X, Li Y, Lao H, Zhang Y, Dong H, Xu W, Li JL, Li M. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway. Hepatology. 2011a;53:1932–1942. doi: 10.1002/hep.24291. [DOI] [PubMed] [Google Scholar]
  • Wang et al. (2013).Wang S, Li H, Wang J, Wang D. Expression of microRNA-497 and its prognostic significance in human breast cancer. Diagnostic Pathology. 2013;8:172. doi: 10.1186/1746-1596-8-172. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • Wang & Lin (2013).Wang SE, Lin RJ. MicroRNA and HER2-overexpressing cancer. Microrna. 2013;2:137–147. doi: 10.2174/22115366113029990011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wang et al. (2011b).Wang X, Liu X, Li AY, Chen L, Lai L, Lin HH, Hu S, Yao L, Peng J, Loera S, Xue L, Zhou B, Zhou L, Zheng S, Chu P, Zhang S, Ann DK, Yen Y. Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. Clinical Cancer Research. 2011b;17:2570–2580. doi: 10.1158/1078-0432.CCR-10-2542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wang & Luo (2015).Wang W, Luo YP. MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. Journal of Zhejiang University Science B. 2015;16:18–31. doi: 10.1631/jzus.B1400184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Wu et al. (2013).Wu ZB, Cai L, Lin SJ, Lu JL, Yao Y, Zhou LF. The miR-92b functions as a potential oncogene by targeting on Smad3 in glioblastomas. Brain Research. 2013;1529:16–25. doi: 10.1016/j.brainres.2013.07.031. [DOI] [PubMed] [Google Scholar]
  • Yakovchuk, Protozanova & Frank-Kamenetskii (2006).Yakovchuk P, Protozanova E, Frank-Kamenetskii MD. Base-stacking and base-pairing contributions into thermal stability of the DNA double helix. Nucleic Acids Research. 2006;34:564–574. doi: 10.1093/nar/gkj454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yang, Sui & Liang (2017).Yang S, Sui J, Liang G. Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma: a study based on the Cancer Genome Atlas. PeerJ. 2017;5:e4101. doi: 10.7717/peerj.4101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yang et al. (2017).Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H, Teschendorff AE. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Research. 2017;45:D812–D818. doi: 10.1093/nar/gkw1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yao et al. (2018).Yao L, Liu Y, Cao Z, Li J, Huang Y, Hu X, Shao Z. MicroRNA-493 is a prognostic factor in triple-negative breast cancer. Cancer Science. 2018;109:2294–2301. doi: 10.1111/cas.13644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • Yu et al. (2013).Yu Y, Wu J, Guan L, Qi L, Tang Y, Ma B, Zhan J, Wang Y, Fang W, Zhang H. Kindlin 2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family. International Journal of Cancer. 2013;133:1368–1379. doi: 10.1002/ijc.28151. [DOI] [PubMed] [Google Scholar]
  • Yurikova et al. (2019).Yurikova OYu, Aisina DE, Niyazova RE, Atambayeva ShA, Labeit S, Ivashchenko AT. The Interaction of miRNA-5p and miRNA-3p with the mRNAs of Orthologous Genes. Molecular Biology. 2019;53:1–13. doi: 10.1134/S0026893319010163. [DOI] [PubMed] [Google Scholar]
  • Zhang et al. (2017).Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC, Ma R. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene. 2017;619:10–20. doi: 10.1016/j.gene.2017.03.038. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer triple-negative subtype.
DOI: 10.7717/peerj.8049/supp-1
Figure S2. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer luminal A and B subtypes.
DOI: 10.7717/peerj.8049/supp-2
Figure S3. Schemes of miRNA interaction with mRNA of candidate genes of breast cancer HER2 subtype.
DOI: 10.7717/peerj.8049/supp-3
Table S1. Candidate genes of subtypes of breast cancer, indicating sources of information on their participation in oncogenesis of breast cancer.
DOI: 10.7717/peerj.8049/supp-4
Table S2. Information on miRNAs interacted with genes of breast cancer and other cancer.
DOI: 10.7717/peerj.8049/supp-5
Table S3. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of triple-negative subtype.
DOI: 10.7717/peerj.8049/supp-6
Table S4. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of luminal A and B subtypes.
DOI: 10.7717/peerj.8049/supp-7
Table S5. The nucleotide sequence of clusters of miRNA binding sites in orthologous candidate genes of HER2 subtype.
DOI: 10.7717/peerj.8049/supp-8

Data Availability Statement

The following information was supplied regarding data availability:

The nucleotide sequences of candidate genes (ID) of BC subtypes are available at NCBI. The accession numbers are in Table S1.

The nucleotide sequences of 2565 miRNAs from miRBase and 3707 miRNAs are available from: Novel primate- and tissue-specific microRNAs, Proceedings of the National Academy of Sciences Mar 2015, 112 (10) E1106–E1115; DOI: 10.1073/pnas.1420955112

Protein expression was found by the corresponding gene (ID) in the Human Protein Atlas. Reads Per Kilobase Million (RPKM) value is available in the Human Protein Atlas data (https://www.proteinatlas.org/ENSG00000150093-ITGB1/tissue/breast).


Articles from PeerJ are provided here courtesy of PeerJ, Inc

RESOURCES